{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:13:40Z","timestamp":1790633620449,"version":"4.1.0"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br Dent J"],"published-print":{"date-parts":[[2025,11,14]]},"DOI":"10.1038\/s41415-025-8643-1","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T10:08:35Z","timestamp":1763114915000},"page":"613-619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A literature review and update on medications related to osteonecrosis of the jaw independent of bisphosphonates and denosumab"],"prefix":"10.1038","volume":"239","author":[{"given":"Nadeen","family":"Jawad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"8643_CR3943","doi-asserted-by":"crossref","unstructured":"Marx R E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115\u20131117.","DOI":"10.1016\/S0278-2391(03)00720-1"},{"key":"8643_CR3947","doi-asserted-by":"crossref","unstructured":"Scagliotti G V, Hirsh V, Siena S et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 2012; 7: 1823\u20131829.","DOI":"10.1097\/JTO.0b013e31826aec2b"},{"key":"8643_CR3951","unstructured":"Scottish Dental Clinical Effectiveness Programme. Oral health management of patients at risk of medication-related osteonecrosis of the jaw. 2024. Available at https:\/\/www.sdcep.org.uk\/published-guidance\/medication-related-osteonecrosis-of-the-jaw\/ (accessed 1 November 2024)."},{"key":"8643_CR3955","doi-asserted-by":"crossref","unstructured":"King R, Tanna N, Patel V. Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab \u2013 a review. Oral Surg Oral Med Oral Pathol Oral Radiol 2019; 127: 289\u2013299.","DOI":"10.1016\/j.oooo.2018.11.012"},{"key":"8643_CR3959","doi-asserted-by":"crossref","unstructured":"Oguntade A S, Al-Amodi F, Alrumayh A, Alobaida M, Bwalya M. Anti-angiogenesis in cancer therapeutics: the magic bullet. J Egypt Natl Cancer Inst 2021; 33: 15.","DOI":"10.1186\/s43046-021-00072-6"},{"key":"8643_CR3963","doi-asserted-by":"crossref","unstructured":"Watanabe R, Wei L, Huang J. mTOR signaling, function, novel inhibitors, and therapeutic targets. J Nucl Med 2011; 52: 497\u2013500.","DOI":"10.2967\/jnumed.111.089623"},{"key":"8643_CR3967","doi-asserted-by":"crossref","unstructured":"Bruland O S, Jonasdottir T J, Fisher D R, Larsen R H. Radium-223: from radiochemical development to clinical applications in targeted cancer therapy. Curr Radiopharm 2008; 1: 203\u2013208.","DOI":"10.2174\/1874471010801030203"},{"key":"8643_CR3971","doi-asserted-by":"crossref","unstructured":"Kordella C, Lamprianidou E, Kotsianidis I. Mechanisms of action of hypomethylating agents: endogenous retroelements at the epicenter. Front Oncol 2021; 11: 650473.","DOI":"10.3389\/fonc.2021.650473"},{"key":"8643_CR3975","doi-asserted-by":"crossref","unstructured":"Lee B-W, Moon S-J. Inflammatory cytokines in psoriatic arthritis: understanding pathogenesis and implications for treatment. Int J Mol Sci 2023; 24: 11662.","DOI":"10.3390\/ijms241411662"},{"key":"8643_CR3979","doi-asserted-by":"crossref","unstructured":"Gharwan H, Groninger H. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol 2016; 13: 209\u2013227.","DOI":"10.1038\/nrclinonc.2015.213"},{"key":"8643_CR3983","doi-asserted-by":"crossref","unstructured":"Arora A, Scholar E M. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315: 971\u2013979.","DOI":"10.1124\/jpet.105.084145"},{"key":"8643_CR3987","doi-asserted-by":"crossref","unstructured":"Madhusudan S, Ganesan T S. Tyrosine kinase inhibitors in cancer therapy. Clin Biochem 2004; 37: 618\u2013635.","DOI":"10.1016\/j.clinbiochem.2004.05.006"},{"key":"8643_CR3991","unstructured":"Leukemia and Lymphoma Society Tyrosine kinase inhibitor (TKI) therapy. 2017. Available at https:\/\/bloodcancerunited.org\/blood-cancer\/leukemia\/chronic-myeloid-leukemia-cml\/treatment (accessed 1 November 2024)."},{"key":"8643_CR3995","doi-asserted-by":"crossref","unstructured":"Nakagawa M, Kaneda T, Arakawa T et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 2000; 473: 161\u2013164.","DOI":"10.1016\/S0014-5793(00)01520-9"},{"key":"8643_CR3999","unstructured":"Thomson R J, Moshirfar M, Ronquillo Y. Tyrosine Kinase Inhibitors. Florida: StatPearls Publishing, 2023."},{"key":"8643_CR4003","unstructured":"National Institute for Health and Care Excellence. Axitinib [specialist drug]. Available at https:\/\/bnf.nice.org.uk\/drugs\/axitinib-specialist-drug\/ (accessed 1 November 2024)."},{"key":"8643_CR4007","doi-asserted-by":"crossref","unstructured":"Patel V, Sproat C, Kwok J, Tanna N. Axitinib-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 2017; DOI: 10.1016\/j.oooo.2017.08.003.","DOI":"10.1016\/j.oooo.2017.08.003"},{"key":"8643_CR4011","unstructured":"National Institute for Health and Care Excellence. Cabozantinib [specialist drug]. Available at https:\/\/bnf.nice.org.uk\/drugs\/cabozantinib-specialist-drug\/ (accessed 1 November 2024)."},{"key":"8643_CR4016","doi-asserted-by":"crossref","unstructured":"Marino R, Orlandi F, Arecco F, Gandolfo S, Pentenero M. Osteonecrosis of the jaw in a patient receiving cabozantinib. Aust Dent J 2015; 60: 528\u2013531.","DOI":"10.1111\/adj.12254"},{"key":"8643_CR4020","doi-asserted-by":"crossref","unstructured":"Elisei R, Schlumberger M J, M\u00fcller S P et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013; 31: 3639\u20133646.","DOI":"10.1200\/JCO.2012.48.4659"},{"key":"8643_CR4025","unstructured":"National Institute for Health and Care Excellence. Dasatinib [specialist drug]. Available at https:\/\/bnf.nice.org.uk\/drugs\/dasatinib-specialist-drug\/ (accessed 1 November 2024)."},{"key":"8643_CR4030","doi-asserted-by":"crossref","unstructured":"Won A M, Boddu P, Otun A O, Aponte-Wesson R, Chambers M. Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol 2018; DOI: 10.1016\/j.oooo.2018.05.008.","DOI":"10.1016\/j.oooo.2018.05.008"},{"key":"8643_CR4034","doi-asserted-by":"crossref","unstructured":"Mohamed H A, Nielsen C E, Schiodt M. Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen. Cohort Oral Surg Oral Med Oral Pathol Oral Radiol 2018; 125: 157\u2013163.","DOI":"10.1016\/j.oooo.2017.10.010"},{"key":"8643_CR4038","unstructured":"National Institute for Health and Care Excellence. Ibrutinib [specialist drug]. Available at https:\/\/bnf.nice.org.uk\/drugs\/ibrutinib-specialist-drug\/ (accessed 1 November 2024)."},{"key":"8643_CR4042","doi-asserted-by":"crossref","unstructured":"Singh A, Na S, Huryn J M, Estilo C L, Horwitz S, Yom S K. Ibrutinib-associated osteonecrosis of the jaw. Oral Oncol Rep 2024; 9: 100228.","DOI":"10.1016\/j.oor.2024.100228"},{"key":"8643_CR4046","unstructured":"National Institute for Health and Care Excellence. Imantinib [specialist drug]. Available at https:\/\/bnf.nice.org.uk\/drugs\/imatinib-specialist-drug\/ (accessed 1 November 2024)."},{"key":"8643_CR4050","doi-asserted-by":"crossref","unstructured":"Viviano M, Rossi M, Cocca S. A rare case of osteonecrosis of the jaw related to imatinib. J Korean Assoc Oral Maxillofac Surg 2017; 43: 120\u2013124.","DOI":"10.5125\/jkaoms.2017.43.2.120"},{"key":"8643_CR4054","doi-asserted-by":"crossref","unstructured":"Okubo-Sato M, Yamagata K, Fukuzawa S et al. Medication-related osteonecrosis of the jaw spontaneously occurred in a patient with chronic myelogenous leukemia only by imatinib: a report of a rare case. Case Rep Dent 2021; 2021: 6621937.","DOI":"10.1155\/2021\/6621937"},{"key":"8643_CR4059","doi-asserted-by":"crossref","unstructured":"Yeh C-N, Fu C-J, Yen T-C, Chiang K-C, Jan Y-Y, Chen M-F. Osteonecrosis of the tibia associated with imatinib in metastatic GI stromal tumor. J Clin Oncol 2013; DOI: 10.1200\/JCO.2012.45.1294.","DOI":"10.1200\/JCO.2012.45.1294"},{"key":"8643_CR4063","unstructured":"National Institute for Health and Care Excellence. Lenvatinib [specialist drug]. Available at https:\/\/bnf.nice.org.uk\/drugs\/lenvatinib-specialist-drug\/ (accessed 1 November 2024)."},{"key":"8643_CR4068","doi-asserted-by":"crossref","unstructured":"Mauceri R, Panzarella V, Morreale I, Campisi G. Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib. Int J Oral Maxillofac Surg 2019; 48: 1530\u20131532.","DOI":"10.1016\/j.ijom.2019.07.010"},{"key":"8643_CR4072","unstructured":"National Institute for Health and Care Excellence. Nintedanib. Available at https:\/\/bnf.nice.org.uk\/drugs\/nintedanib\/ (accessed 1 November 2024)."},{"key":"8643_CR4076","doi-asserted-by":"crossref","unstructured":"Kudva A, Saha M, Srikanth G, Arun S, Sharma S. Nintedanib-induced osteomyelitis of the jaw against the background of COVID-19 infection. J Stomatol Oral Maxillofac Surg 2024; 125: 101651.","DOI":"10.1016\/j.jormas.2023.101651"},{"key":"8643_CR4080","doi-asserted-by":"crossref","unstructured":"Rai O, Romero K N, Shaykh N et al. A jaw-dropping consequence: nintedanib's role in osteonecrosis of the jaw. Cureus 2024; DOI: 10.7759\/cureus.65689.","DOI":"10.7759\/cureus.65689"},{"key":"8643_CR4084","unstructured":"National Institute for Health and Care Excellence. Osimertinib [specialist drug]. Available at https:\/\/bnf.nice.org.uk\/drugs\/osimertinib-specialist-drug\/ (accessed 1 November 2024)."},{"key":"8643_CR4088","doi-asserted-by":"crossref","unstructured":"Subramanian G, Kashikar S, Fitzhugh V, Quek S Y. Osimertinib and jaw osteonecrosis? A case report. Int J Cancer 2019; 145: 2003\u20132005.","DOI":"10.1002\/ijc.32399"},{"key":"8643_CR4092","doi-asserted-by":"crossref","unstructured":"Forte M, d'Amati A, Limongelli L et al. Could MRONJ be related to osimertinib monotherapy in lung cancer patients after denosumab suspension? Healthcare 2024; 12: 457.","DOI":"10.3390\/healthcare12040457"},{"key":"8643_CR4096","unstructured":"National Institute for Health and Care Excellence. Pazopanib [specialist drug]. Available at https:\/\/bnf.nice.org.uk\/drugs\/pazopanib-specialist-drug\/ (accessed 1 November 2024)."},{"key":"8643_CR4101","doi-asserted-by":"crossref","unstructured":"Jung T-Y. Osteonecrosis of jaw after antiangiogenic agent administration in a renal cell carcinoma patient. Oral Maxillofac Surg Cases 2017; 3: 27\u201333.","DOI":"10.1016\/j.omsc.2017.03.001"},{"key":"8643_CR4105","doi-asserted-by":"crossref","unstructured":"Papadopoulou E, Vardas E, Tziveleka S et al. Oral side effects in patients with metastatic renal cell carcinoma receiving the antiangiogenic agent pazopanib \u2013 report of three cases. Dent J 2022; 10: 232.","DOI":"10.3390\/dj10120232"},{"key":"8643_CR4110","unstructured":"National Institute for Health and Care Excellence. Regorafenib [specialist drug]. Available at https:\/\/bnf.nice.org.uk\/drugs\/regorafenib-specialist-drug\/ (accessed 1 November 2024)."},{"key":"8643_CR4114","doi-asserted-by":"crossref","unstructured":"Antonuzzo L, Lunghi A, Giommoni E, Brugia M, Di Costanzo F. Regorafenib also can cause osteonecrosis of the jaw. J Natl Cancer Inst 2016; DOI: 10.1093\/jnci\/djw002.","DOI":"10.1093\/jnci\/djw002"},{"key":"8643_CR4118","unstructured":"National Institute for Health and Care Excellence. Sorafenib [specialist drug]. Available at https:\/\/bnf.nice.org.uk\/drugs\/sorafenib-specialist-drug\/ (accessed 1 November 2024)."},{"key":"8643_CR4122","doi-asserted-by":"crossref","unstructured":"Garuti F, Camelli V, Spinardi L, Bucci L, Trevisani F. Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma. Tumori J 2016; DOI: 10.5301\/tj.5000504.","DOI":"10.5301\/tj.5000504"},{"key":"8643_CR4126","doi-asserted-by":"crossref","unstructured":"Kapagan T, Bulut N, Unsal A, Erdem G U. Sorafenib-associated bilateral osteonecrosis of the femoral head. Am J Ther 2024; OI: 10.1097\/MJT.0000000000001751.","DOI":"10.1097\/MJT.0000000000001751"},{"key":"8643_CR4130","unstructured":"National Institute for Health and Care Excellence. Sunitinib [specialist drug]. Available at https:\/\/bnf.nice.org.uk\/drugs\/sunitinib-specialist-drug\/ (accessed 1 November 2024)."},{"key":"8643_CR4134","doi-asserted-by":"crossref","unstructured":"Vallina C, Ramirez L, Torres J, Casanas E, Hernandez G, Lopez-Pintor R M. Osteonecrosis of the jaws produced by sunitinib: a systematic review. Med Oral Patol Oral Cir Bucal 2019; DOI: 10.4317\/medoral.22858.","DOI":"10.4317\/medoral.22858"},{"key":"8643_CR4138","doi-asserted-by":"crossref","unstructured":"Ashrafi F, Derakhshandeh A, Movahedian B, Moghaddas A. Osteonecrosis of the jaws in patient received bisphosphonates and sunitinib separately: a case report. J Res Pharm Pract 2017; 6: 182\u2013185.","DOI":"10.4103\/jrpp.JRPP_17_36"},{"key":"8643_CR4143","doi-asserted-by":"crossref","unstructured":"Fusco V, Porta C, Saia G et al. Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: results of an Italian multicenter study and review of the literature. Clin Genitourin Cancer 2015; 13: 287\u2013294.","DOI":"10.1016\/j.clgc.2014.12.002"},{"key":"8643_CR4147","doi-asserted-by":"crossref","unstructured":"Christodoulou C, Pervena A, Klouvas G et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009; 76: 209\u2013211.","DOI":"10.1159\/000201931"},{"key":"8643_CR4152","unstructured":"Zheng Y, Jiang Y. mTOR inhibitors at a glance. Mol Cell Pharmacol 2015; 7: 15\u201320."},{"key":"8643_CR4157","doi-asserted-by":"crossref","unstructured":"Xie J, Wang X, Proud C G. mTOR inhibitors in cancer therapy. F1000Res 2016; DOI: 10.12688\/f1000research.9207.1.","DOI":"10.12688\/f1000research.9207.1"},{"key":"8643_CR4161","doi-asserted-by":"crossref","unstructured":"Zhang X, Hamadeh I S, Song S et al. Osteonecrosis of the jaw in the United States Food and Drug Administration's adverse event reporting system (FAERS). J Bone Miner Res 2016; 31: 336\u2013340.","DOI":"10.1002\/jbmr.2693"},{"key":"8643_CR4165","unstructured":"National Institute for Health and Care Excellence. Everolimus. Available at https:\/\/bnf.nice.org.uk\/drugs\/everolimus\/ (accessed 1 November 2024)."},{"key":"8643_CR4169","doi-asserted-by":"crossref","unstructured":"Akkach S, Shukla L, Morgan D. Everolimus-induced osteonecrosis of the jaw in the absence of bisphosphonates: a case report. Br J Oral Maxillofac Surg 2019; 57: 688\u2013690.","DOI":"10.1016\/j.bjoms.2019.05.017"},{"key":"8643_CR4173","doi-asserted-by":"crossref","unstructured":"Yamamoto D, Tsubota Y, Utsunomiya T et al. Osteonecrosis of the jaw associated with everolimus: a case report. Mol Clin Oncol 2017; 6: 255\u2013257.","DOI":"10.3892\/mco.2016.1100"},{"key":"8643_CR4177","doi-asserted-by":"crossref","unstructured":"Lee C Y, Lee K L, Hirata K Y, Suzuki J B. Medication-related osteonecrosis of the jaw with the mTOR inhibitor everolimus in a patient with estrogen-receptor positive breast cancer: a case report. Int J Oral Dent Health 2016; 2: 3.","DOI":"10.23937\/2469-5734\/1510033"},{"key":"8643_CR4183","unstructured":"Giancola F, Campisi G, Russo L L, Muzio L L, Di Fede O. Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report? Ann Stomatol 2013; 4: 20\u201321."},{"key":"8643_CR4188","doi-asserted-by":"crossref","unstructured":"Kim D W, Jung Y-S, Park H-S, Jung H-D. Osteonecrosis of the jaw related to everolimus: a case report. Br J Oral Maxillofac Surg 2013; DOI: 10.1016\/j.bjoms.2013.09.008.","DOI":"10.1016\/j.bjoms.2013.09.008"},{"key":"8643_CR4192","unstructured":"National Institute for Health and Care Excellence. Temsirolimus [specialist drug]. Available at https:\/\/bnf.nice.org.uk\/drugs\/temsirolimus-specialist-drug\/ (accessed 1 November 2024)."},{"key":"8643_CR4199","doi-asserted-by":"crossref","unstructured":"Fusco V, Porta C, Saia G et al. Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: results of an Italian multicenter study and review of the literature. Clin Genitourin Cancer 2015; 13: 287\u2013294.","DOI":"10.1016\/j.clgc.2014.12.002"},{"key":"8643_CR4203","doi-asserted-by":"crossref","unstructured":"Nifos\u00ec A F, Nifos\u00ec L, Nifos\u00ec G. Osteonecrosis of the jaw in a patient treated with denosumab and temsirolimus. SAJ Case Rep 2017; 4: 401.","DOI":"10.18875\/2375-7043.4.401"},{"key":"8643_CR4207","doi-asserted-by":"crossref","unstructured":"Santos-Silva A R, Rosa G A, de Castro J\u00fanior G, Dias R B, Ribeiro A C, Brand\u00e3o T B. Osteonecrosis of the mandible associated with bevacizumab therapy. Oral Surg Oral Med Oral Pathol Oral Radiol 2013; DOI: 10.1016\/j.oooo.2013.02.001.","DOI":"10.1016\/j.oooo.2013.02.001"},{"key":"8643_CR4211","unstructured":"Agrillo A, Nastro Siniscalchi E, Facchini A, Filiaci F, Ungari C. Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports. Eur Rev Med Pharmacol Sci 2012; 16: 952\u2013957."},{"key":"8643_CR4217","doi-asserted-by":"crossref","unstructured":"Coulson A, Levy A, Gossell-Williams M. Monoclonal antibodies in cancer therapy: mechanisms, successes and limitations. West Indian Med J 2014; 63: 650\u2013654.","DOI":"10.7727\/wimj.2013.241"},{"key":"8643_CR4404","doi-asserted-by":"crossref","unstructured":"Hafeez U, Gan H K, Scott A M. Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. Curr Opin Pharmacol 2018; 41: 114\u2013121.","DOI":"10.1016\/j.coph.2018.05.010"},{"key":"8643_CR4225","unstructured":"American Cancer Society. Monoclonal antibody side effects. Available at https:\/\/www.cancer.org\/cancer\/managing-cancer\/treatment-types\/immunotherapy\/monoclonal-antibodies.html (accessed 1 November 2024)."},{"key":"8643_CR4229","doi-asserted-by":"crossref","unstructured":"Bayer V. An overview of monoclonal antibodies. Semin Oncol Nurs 2019; 35: 150927.","DOI":"10.1016\/j.soncn.2019.08.006"},{"key":"8643_CR4235","unstructured":"National Institute for Health and Care Excellence. Adalimumab. Available at https:\/\/bnf.nice.org.uk\/drugs\/adalimumab\/ (accessed 1 November 2024)."},{"key":"8643_CR4240","doi-asserted-by":"crossref","unstructured":"Sisalli L, Giordano F, Chiacchio A, Acerra A, Caggiano M. Medication-related osteonecrosis of the jaw: a case report of an unusual side effect of adalimumab. Case Rep Dent 2023; 2023: 5544285.","DOI":"10.1155\/2023\/5544285"},{"key":"8643_CR4244","doi-asserted-by":"crossref","unstructured":"Cassoni A, Romeo U, Terenzi V et al. Adalimumab: another medication related to osteonecrosis of the jaws? Case Rep Dent 2016; 2016: 2856926.","DOI":"10.1155\/2016\/2856926"},{"key":"8643_CR4249","unstructured":"National Institute for Health and Care Excellence. Bevacizumab [specialist drug]. Available at https:\/\/bnf.nice.org.uk\/drugs\/bevacizumab-specialist-drug\/ (accessed 1 November 2024)."},{"key":"8643_CR4253","doi-asserted-by":"crossref","unstructured":"Estilo C L, Fornier M, Farooki A, Carlson D, Bohle G 3rd, Huryn J M. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008; 26: 4037\u20134038.","DOI":"10.1200\/JCO.2007.15.5424"},{"key":"8643_CR4257","doi-asserted-by":"crossref","unstructured":"Di\u015fel U, Be\u015fen A A, \u00d6zy\u0131lkan \u00d6, Er E, Canpolat T. A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit. Oral Oncol 2012; DOI: 10.1016\/j.oraloncology.2011.07.030.","DOI":"10.1016\/j.oraloncology.2011.07.030"},{"key":"8643_CR4261","doi-asserted-by":"crossref","unstructured":"Greuter S, Schmid F, Ruhstaller T et al. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol 2008; 19: 2091\u20132092.","DOI":"10.1093\/annonc\/mdn653"},{"key":"8643_CR4265","doi-asserted-by":"crossref","unstructured":"Serra E, Paolantonio M, Spoto G, Mastrangelo F, Tet\u00e8 S, Dolci M. Bevacizumab-related osteonecrosis of the jaw. Int J Immunopathol Pharmacol 2009; 22: 1121\u20131123.","DOI":"10.1177\/039463200902200429"},{"key":"8643_CR4269","unstructured":"National Institute for Health and Care Excellence. Golimumab. Available at https:\/\/bnf.nice.org.uk\/drugs\/golimumab\/ (accessed 1 November 2024)."},{"key":"8643_CR4274","doi-asserted-by":"crossref","unstructured":"De Freitas A L S. Thomaz L A, da Silva Lascane N A, da Silva MV, Mautoni M C. Osteonecrosis associated with golimumab. Oral Surg Oral Med Oral Pathol Oral Radiol 2020; DOI: 10.1016\/j.oooo.2020.04.554.","DOI":"10.1016\/j.oooo.2020.04.554"},{"key":"8643_CR4278","doi-asserted-by":"crossref","unstructured":"Ghosh Y A, Pullara J, Rattan R, Melville J C. Case report: golimumab-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 2023; DOI: 10.1016\/j.oooo.2023.05.017.","DOI":"10.1016\/j.oooo.2023.05.017"},{"key":"8643_CR4283","unstructured":"National Institute for Health and Care Excellence. Guselkumab. Available at https:\/\/bnf.nice.org.uk\/drugs\/guselkumab\/ (accessed 1 November 2024)."},{"key":"8643_CR4287","doi-asserted-by":"crossref","unstructured":"Marotta M, Boffano P, Prota E et al. Guselkumab: A new etiological factor of medication related osteonecrosis of the jaw (MRONJ)? A case report. J Stomatol Oral Maxillofac Surg 2024; 125: 101985.","DOI":"10.1016\/j.jormas.2024.101985"},{"key":"8643_CR4292","unstructured":"National Institute for Health and Care Excellence. Ipilimumab [specialist drug]. Available at https:\/\/bnf.nice.org.uk\/drugs\/ipilimumab-specialist-drug\/ (accessed 1 November 2024)."},{"key":"8643_CR4296","doi-asserted-by":"crossref","unstructured":"Owosho A A, Scordo M, Yom S K et al. Osteonecrosis of the jaw a new complication related to Ipilimumab. Oral Oncol 2015; DOI: 10.1016\/j.oraloncology.2015.08.014.","DOI":"10.1016\/j.oraloncology.2015.08.014"},{"key":"8643_CR4300","doi-asserted-by":"crossref","unstructured":"Guida A, Perri F, Ionna F, Ascierto P A, Grimaldi A M. New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy. Clin Case Rep 2021; 9: 61\u201366.","DOI":"10.1002\/ccr3.3418"},{"key":"8643_CR4304","unstructured":"National Institute for Health and Care Excellence. Infliximab. Available at https:\/\/bnf.nice.org.uk\/drugs\/infliximab\/ (accessed 1 November 2024)."},{"key":"8643_CR4308","doi-asserted-by":"crossref","unstructured":"Favia G, Tempesta A, Limongelli L et al. A case of osteonecrosis of the jaw in a patient with Crohn's disease treated with infliximab. Am J Case Rep 2017; 18: 1351.","DOI":"10.12659\/AJCR.905355"},{"key":"8643_CR4312","doi-asserted-by":"crossref","unstructured":"Oryniak D, Brown M, Cholakis L, Elgazzar R. Case report: development of medication-related osteonecrosis of the jaw in a patient on long-term infliximab therapy. Front Oral Health 2024; 5: 1427060.","DOI":"10.3389\/froh.2024.1427060"},{"key":"8643_CR4316","unstructured":"National Institute for Health and Care Excellence. Pembrolizumab [specialist drug]. Available at https:\/\/bnf.nice.org.uk\/drugs\/pembrolizumab-specialist-drug\/ (accessed 1 November 2024)."},{"key":"8643_CR4320","doi-asserted-by":"crossref","unstructured":"Patel V, Carey B. Pembrolizumab related osteonecrosis of the jaw. Br J Oral Maxillofac Surg 2023; 61: 704\u2013706.","DOI":"10.1016\/j.bjoms.2023.08.241"},{"key":"8643_CR4325","doi-asserted-by":"crossref","unstructured":"Pennings I, Moskowitz A, Shah G, Estilo C, Huryn J M, Yom S K. Osteonecrosis of the jaw associated with pembrolizumab. Oral Surg Oral Med Oral Pathol Oral Radiol 2023; DOI: 10.1016\/j.oooo.2022.12.013.","DOI":"10.1016\/j.oooo.2022.12.013"},{"key":"8643_CR4329","doi-asserted-by":"crossref","unstructured":"Nisi M, Pioli M C, Cinquini C, Izzetti R. Medication-related osteonecrosis of the jaws in a patient treated with pembrolizumab: report of a case and review of the literature. Oral Oncol 2024; 153: 106825.","DOI":"10.1016\/j.oraloncology.2024.106825"},{"key":"8643_CR4334","doi-asserted-by":"crossref","unstructured":"Decaux J, Magremanne M. Medication-related osteonecrosis of the jaw related to epacadostat and pembrolizumab. J Stomatol Oral Maxillofac Surg 2020; 121: 740\u2013742.","DOI":"10.1016\/j.jormas.2020.05.001"},{"key":"8643_CR4338","unstructured":"National Institute for Health and Care Excellence. Ranibizumab [specialist drug]. Available at https:\/\/bnf.nice.org.uk\/drugs\/ranibizumab-specialist-drug\/ (accessed 1 November 2024)."},{"key":"8643_CR4342","doi-asserted-by":"crossref","unstructured":"Oz I, Kaplan I, Kleinman S, Arbel S, Shuster A. Medication-related osteonecrosis of the jaws associated with intravitreal administration of ranibizumab. Int J Oral Maxillofac Surg 2020; 49: 1589\u20131591.","DOI":"10.1016\/j.ijom.2020.05.017"},{"key":"8643_CR4346","unstructured":"National Institute for Health and Care Excellence. Rituximab. Available at https:\/\/bnf.nice.org.uk\/drugs\/rituximab\/ (accessed 1 November 2024)."},{"key":"8643_CR4350","doi-asserted-by":"crossref","unstructured":"Allegra A, Oteri G, Alonci A et al. Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab. J Craniomaxillofac Surg 2014; 42: 279\u2013282.","DOI":"10.1016\/j.jcms.2013.05.014"},{"key":"8643_CR4354","doi-asserted-by":"crossref","unstructured":"Weigert K L, Lewgoy J, Mazzoleni D S, Franco F R, Enriconi L, Sasso J H. Rituximab and osteonecrosis of the jaws: case study. Oral Surg Oral Med Oral Pathol Oral Radiol 2014; DOI: 10.1016\/j.oooo.2013.12.203.","DOI":"10.1016\/j.oooo.2013.12.203"},{"key":"8643_CR4358","doi-asserted-by":"crossref","unstructured":"Keribin P, Guerrot D, Jardin F, Moizan H. Osteonecrosis of the jaw in a patient presenting with post-transplantation lymphoproliferative disorder treated with rituximab: a case report. J Oral Maxillofac Surg 2017; 75: 2599\u20132605.","DOI":"10.1016\/j.joms.2017.05.016"},{"key":"8643_CR4362","doi-asserted-by":"crossref","unstructured":"Javelot M-J, Sergheraert J, Agbo-Godeau S et al. Rituximab as a trigger factor of medication-related osteonecrosis of the jaw. A case report. J Stomatol Oral Maxillofac Surg 2020; 121: 300\u2013304.","DOI":"10.1016\/j.jormas.2019.06.009"},{"key":"8643_CR4367","unstructured":"National Institute for Health and Care Excellence. Romosuzomab. Available at https:\/\/bnf.nice.org.uk\/drugs\/romosozumab\/ (accessed 1 November 2024)."},{"key":"8643_CR4371","doi-asserted-by":"crossref","unstructured":"Cosman F, Crittenden D B, Adachi J D et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 2016; 375: 1532\u20131543.","DOI":"10.1056\/NEJMoa1607948"},{"key":"8643_CR4376","doi-asserted-by":"crossref","unstructured":"Peng J, Wang H, Liu Z et al. Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database. Front Pharmacol 2022; 13: 1017391.","DOI":"10.3389\/fphar.2022.1017391"},{"key":"8643_CR4380","doi-asserted-by":"crossref","unstructured":"Palla B, Anderson J, Miloro M, Moles S, Callahan N. Romosozumab-associated medication-related osteonecrosis of the jaw. Oral Maxillofac Surg Cases 2023; 9: 100318.","DOI":"10.1016\/j.omsc.2023.100318"},{"key":"8643_CR4384","unstructured":"National Institute for Health and Care Excellence. Secukinumab. Available at https:\/\/bnf.nice.org.uk\/drugs\/secukinumab\/ (accessed 1 November 2024)."},{"key":"8643_CR4388","doi-asserted-by":"crossref","unstructured":"Hauer L, Moztarzadeh O, Baghalipour N, Gencur J. Secukinumab causing medication-related osteonecrosis of the jaw, in a patient diagnosed with psoriasis and rheumatoid arthritis. Psoriasis 2024; 14: 115\u2013120.","DOI":"10.2147\/PTT.S490982"},{"key":"8643_CR4392","unstructured":"National Institute for Health and Care Excellence. Tocilizumab. Available at https:\/\/bnf.nice.org.uk\/drugs\/tocilizumab\/ (accessed 1 November 2024)."},{"key":"8643_CR4396","doi-asserted-by":"crossref","unstructured":"Roh T, Jo H, Kim J-Y. Maxillary Bone necrosis in post-COVID-19 patients: possibility of medication-related osteonecrosis of jaws (MRONJ) induced by tocilizumab. J Craniofac Surg 2024; DOI: 10.1097\/SCS.0000000000010184.","DOI":"10.1097\/SCS.0000000000010184"},{"key":"8643_CR4408","unstructured":"Schmidt S R. Fusion-proteins as biopharmaceuticals \u2013 applications and challenges. Curr Opin Drug Discov Devel 2009; 12: 284\u2013295."},{"key":"8643_CR4412","unstructured":"National Institute for Health and Care Excellence. Aflibercept [specialist drug]. Available at https:\/\/bnf.nice.org.uk\/drugs\/aflibercept-specialist-drug\/ (accessed 1 November 2024)."},{"key":"8643_CR4417","unstructured":"European Medicines Agency. ZALTRAP product characteristics. Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zaltrap-epar-product-information_en.pdf (accessed 1 November 2024)."},{"key":"8643_CR4421","doi-asserted-by":"crossref","unstructured":"Mawardi H, Enzinger P, McCleary N et al. Osteonecrosis of the jaw associated with ziv-aflibercept. J Gastrointest Oncol 2016; DOI: 10.21037\/jgo.2016.05.07.","DOI":"10.21037\/jgo.2016.05.07"},{"key":"8643_CR4426","doi-asserted-by":"crossref","unstructured":"Ponzetti A, Pinta F, Spadi R et al. Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district. Tumori 2016; DOI: 10.5301\/tj.5000405","DOI":"10.5301\/tj.5000405"},{"key":"8643_CR4430","doi-asserted-by":"crossref","unstructured":"Zarringhalam P, Brizman E, Shakib K. Medication-related osteonecrosis of the jaw associated with aflibercept. Br J Oral Maxillofac Surg 2017; 55: 314\u2013315.","DOI":"10.1016\/j.bjoms.2016.11.315"},{"key":"8643_CR4434","unstructured":"UK Government. Aflibercept (Zaltrap): minimising the risk of osteonecrosis of the jaw. 2016. Available at https:\/\/www.gov.uk\/drug-safety-update\/aflibercept-zaltrap-minimising-the-risk-of-osteonecrosis-of-the-jaw (accessed 1 November 2024)."},{"key":"8643_CR4438","unstructured":"Galindo A. What are radiopharmaceuticals? 2025. Available at https:\/\/www.iaea.org\/newscenter\/news\/what-are-radiopharmaceuticals (accessed 1 October 2025)."},{"key":"8643_CR4442","doi-asserted-by":"crossref","unstructured":"Choi J Y. Treatment of bone metastasis with bone-targeting radiopharmaceuticals. Nucl Med Mol Imaging 2018; 52: 200\u2013207.","DOI":"10.1007\/s13139-017-0509-2"},{"key":"8643_CR4446","unstructured":"National Institute for Health and Care Excellence. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases. 2016. Available at https:\/\/www.nice.org.uk\/guidance\/ta412\/resources\/radium223-dichloride-for-treating-hormonerelapsed-prostate-cancer-with-bone-metastases-pdf-82604599866565 (accessed 1 November 2024)."},{"key":"8643_CR4450","doi-asserted-by":"crossref","unstructured":"Wieder H A, Lassmann M, Allen-Auerbach M S, Czernin J, Herrmann K. Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters. World J Radiol 2014; 6: 480\u2013285.","DOI":"10.4329\/wjr.v6.i7.480"},{"key":"8643_CR4454","doi-asserted-by":"crossref","unstructured":"Saad F, Brown J E, Van Poznak C et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23: 1341\u20131347.","DOI":"10.1093\/annonc\/mdr435"},{"key":"8643_CR4459","unstructured":"Center for Drug Evaluation and Research. 203971Orig1s000 cross discipline team leader review. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/203971Orig1s000CrossR.pdf (accessed 1 November 2024)."},{"key":"8643_CR4463","doi-asserted-by":"crossref","unstructured":"Herlofson B B, Kj\u00f8lle G K, Westgaard K L, L\u00f8ndalen A M, Bruland \u00d8 S. Osteonecrosis of the jaw in a patient with bone metastatic prostate cancer after long-term bisphosphonate treatment with severe deterioration following radium-223. Clin Genitourin Cancer 2018; 16: 328\u2013331.","DOI":"10.1016\/j.clgc.2018.05.003"},{"key":"8643_CR4468","doi-asserted-by":"crossref","unstructured":"Howell P M, Liu Z, Khong H T. Demethylating agents in the treatment of cancer. Pharmaceuticals 2010; 3: 2022\u20132044.","DOI":"10.3390\/ph3072022"},{"key":"8643_CR4472","unstructured":"National Institute for Health and Care Excellence. Azacitidine [specialist drug]. Available at https:\/\/bnf.nice.org.uk\/drugs\/azacitidine-specialist-drug\/ (accessed 1 November 2024)."},{"key":"8643_CR4478","doi-asserted-by":"crossref","unstructured":"Nicolatou-Galitis O, Galiti D, Moschogianni M et al. Osteonecrosis of the jaw in a patient with acute myeloid leukemia, who received azacitidine. J Cancer Metasta Treat 2016; 2: 220\u2013223.","DOI":"10.20517\/2394-4722.2016.06"},{"key":"8643_CR4482","doi-asserted-by":"crossref","unstructured":"Chan C C. Selective estrogen receptor modulators. Gynecol Drug Ther 2016; 105\u2013110.","DOI":"10.3109\/9781420016345-13"},{"key":"8643_CR4486","unstructured":"National Institute for Health and Care Excellence. Raloxifene hydrochloride. Available at https:\/\/bnf.nice.org.uk\/drugs\/raloxifene-hydrochloride\/ (accessed 1 November 2024)."},{"key":"8643_CR4490","unstructured":"Baur D A, Altay M A, Teich S, Oswald M S, Quereshy F A. Osteonecrosis of the jaw in a patient on raloxifene: a case report. Quintessence Int 2015; 46: 423\u2013428."},{"key":"8643_CR4494","doi-asserted-by":"crossref","unstructured":"Pontes H A, de Souza L L, Uch\u00f4a D C, Cerqueira J M. Mandibular osteonecrosis associated with raloxifene. J Craniofac Surg 2018; DOI: 10.1097\/SCS.0000000000004278.","DOI":"10.1097\/SCS.0000000000004278"},{"key":"8643_CR4498","unstructured":"Bindakhil M, Shanti R M, Mupparapu M. Raloxifene-induced osteonecrosis of the jaw (MRONJ) with no exposure to bisphosphonates: clinical and radiographic findings. Quintessence Int 2021; 52: 258\u2013263."},{"key":"8643_CR4503","doi-asserted-by":"crossref","unstructured":"Cronstein B N. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997; 23: 739\u2013755.","DOI":"10.1016\/S0889-857X(05)70358-6"},{"key":"8643_CR4507","unstructured":"National Institute for Health and Care Excellence. Methotrexate. Available at https:\/\/bnf.nice.org.uk\/drugs\/methotrexate\/ (accessed 1 November 2024)."},{"key":"8643_CR4512","doi-asserted-by":"crossref","unstructured":"Annussek T, Kleinheinz J, Thomas S, Joos U, Wermker K. Short time administration of antirheumatic drugs-methotrexate as a strong inhibitor of osteoblast's proliferation in vitro. Head Face Med 2012; 8: 26.","DOI":"10.1186\/1746-160X-8-26"},{"key":"8643_CR4516","doi-asserted-by":"crossref","unstructured":"Sklavos A W, Delpachitra S N, Thomas A M, Nastri A. Spontaneous bilateral osteonecrosis of the mandible in a bisphosphonate-naive patient. Br J Oral Maxillofac Surg 2019; 57: 271\u2013274.","DOI":"10.1016\/j.bjoms.2019.01.015"},{"key":"8643_CR4520","doi-asserted-by":"crossref","unstructured":"Aghaloo T L, Tetradis S. Osteonecrosis of the jaw in the absence of antiresorptive or antiangiogenic exposure: a series of 6 cases. J Oral Maxillofac Surg 2017; 75: 129\u2013142.","DOI":"10.1016\/j.joms.2016.07.019"},{"key":"8643_CR4525","doi-asserted-by":"crossref","unstructured":"Henien M, Carey B, Hullah E, Sproat C, Patel V. Methotrexate-associated osteonecrosis of the jaw: a report of two cases. Oral Surg Oral Med Oral Pathol Oral Radiol 2017; DOI: 10.1016\/j.oooo.2017.09.005.","DOI":"10.1016\/j.oooo.2017.09.005"},{"key":"8643_CR4529","doi-asserted-by":"crossref","unstructured":"Ramamoorthy S, Cidlowski J A. Corticosteroids: mechanisms of action in health and disease. Rheum Dis Clin 2016; 42: 15\u201331.","DOI":"10.1016\/j.rdc.2015.08.002"},{"key":"8643_CR4533","doi-asserted-by":"crossref","unstructured":"Weinstein R S. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am 2012; 41: 595\u2013611.","DOI":"10.1016\/j.ecl.2012.04.004"},{"key":"8643_CR4539","doi-asserted-by":"crossref","unstructured":"Wong L-S, Tay K-K, Chieng Y-L. Osteonecrosis of mandible: a rare complication of long-term steroid use. J Oral Maxillofac Surg Med Pathol 2015; 27: 255\u2013257.","DOI":"10.1016\/j.ajoms.2014.05.009"},{"key":"8643_CR4543","unstructured":"Nisi M, La Ferla F, Graziani F, Gabriele M. Osteonecrosis of the jaws related to corticosteroids therapy: a case report. Ann Stomatol 2014; 5: 29\u201330."}],"container-title":["British Dental Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41415-025-8643-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41415-025-8643-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41415-025-8643-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T10:09:04Z","timestamp":1763114944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41415-025-8643-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":139,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,11,14]]}},"alternative-id":["8643"],"URL":"https:\/\/doi.org\/10.1038\/s41415-025-8643-1","relation":{},"ISSN":["0007-0610","1476-5373"],"issn-type":[{"value":"0007-0610","type":"print"},{"value":"1476-5373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"28 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}}]}}